International GLP-1 Price Arbitrage in 2026

International GLP-1 arbitrage still exists, but the U.S. price cuts have narrowed the gap. Here's what international channels actually cost in 2026 and when they still make sense.

U.S. drug prices have historically been the highest in the developed world, and GLP-1 medications have been no exception. Wegovy, Ozempic, and Zepbound have list prices in the U.S. that are multiples of the prices available in Canada, the United Kingdom, Germany, Denmark (Novo's home market), and other developed economies. This price differential has driven a persistent practice of international price arbitrage — U.S. patients obtaining GLP-1 medications through international pharmacies, either directly or through traveling to access foreign markets.

With U.S. cash-pay prices having fallen substantially in 2025-2026, the economics of international arbitrage have shifted. For some patients and some doses, international channels remain meaningfully cheaper; for others, the U.S. cash-pay programs have closed the gap sufficiently that the administrative complexity of international arbitrage no longer pays off.

International GLP-1 Pricing Reference

These are rough 2025-2026 approximations for brand-name semaglutide or tirzepatide, converted to U.S. dollar equivalents at current exchange rates. Actual prices vary by pharmacy, dose strength, and local pricing policies. Some markets have additional subsidies, reimbursement programs, or wholesale purchasing arrangements that further reduce patient out-of-pocket costs.

How International Arbitrage Works in Practice

U.S. patients access international GLP-1 pricing through several mechanisms. Direct-to-consumer international pharmacies (primarily Canadian and European-based) ship medications to U.S. addresses, operating in a legal gray zone under U.S. personal-importation policy. Medical tourism — patients traveling to Mexico, Canada, or other countries specifically to purchase medications — avoids the cross-border shipping issue but adds travel costs. Proxy purchases through friends or family in foreign countries operate on a personal basis.

The legal framework for personal importation is complicated. The FDA's general policy has been to not prosecute individual-patient importation of reasonable quantities for personal use, particularly for medications not readily available in the U.S. This enforcement discretion is not a guarantee, and changes in policy or enforcement priorities can alter the practical reality.

Why the Arbitrage Economics Have Shifted

The substantial reduction in U.S. cash-pay prices has narrowed the arbitrage opportunity significantly. When U.S. cash-pay was $1,200-$1,400 and Canadian pricing was $400-$500, the savings justified most administrative and legal complexity. With U.S. cash-pay now $249-$449 through authorized channels, the savings relative to Canadian or U.K. pricing are $50-$200 per month — meaningful but often not enough to justify the logistics and regulatory uncertainty.

Patients who still benefit most from international arbitrage are those at the highest doses (where U.S. cash-pay pricing scales up but some international pricing doesn't), patients without access to authorized U.S. channels, and patients whose cost sensitivity is high enough that even small monthly savings justify the complexity.

Quality and Authenticity Concerns

A real risk with international arbitrage is that not every "international pharmacy" is what it claims to be. Counterfeit, diverted, or improperly handled medications have appeared in the supply chain for high-demand drugs like GLP-1s. Patients considering international arbitrage should verify pharmacy licensure through the regulatory body in the relevant country, look for evidence of legitimate commercial operation, and be skeptical of prices that seem implausibly low.

The best verification is often through national pharmacy regulator websites — the Canadian International Pharmacy Association, the UK's General Pharmaceutical Council, and equivalents. These organizations maintain registers of licensed pharmacies in their jurisdictions. Operations outside the regulated framework carry higher counterfeit and quality risks.

The Current Recommendation

The practical guidance for most U.S. patients in 2026 is to first exhaust authorized U.S. channels — NovoCare, LillyDirect, authorized telehealth subscriptions, commercial insurance copay, and applicable patient assistance programs. If these channels are unaffordable or inaccessible, international arbitrage through verified legitimate pharmacies may be a reasonable option for some patients, with full awareness of the legal and quality considerations.

What Could Change This Analysis

Several policy developments could reshape the international arbitrage landscape. A more permissive U.S. drug importation framework could formalize and expand safe cross-border channels. Tighter enforcement could reduce the availability of current direct-to-consumer international options. Further U.S. price compression could eliminate the economic rationale entirely. For related reporting, see our Wegovy pricing timeline and retail pharmacy pricing reference.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.